Curis

Curis Net Change in Cash

The Net Change in Cash of Curis (CRIS) as of Nov 20, 2026 is -14.94 M USD. In the previous year, Net Change in Cash was -6.68 M USD — a change of 123.46% (lower).

Net Change in Cash

-14.94 MUSD

YoY

123.46%

Last updated:

Net Change in Cash of Curis is 2025 -14.94 M USD. Net Change in Cash of Curis was 2024 -6.68 M USD. It decreases by 123.46% lower compared to the previous year.

The Curis Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-14.65 M USD
Jan 1, 2019
-8.05 M USD
Jan 1, 2020
114.03 M USD
Jan 1, 2021
-89.69 M USD
Jan 1, 2022
-20.45 M USD
Jan 1, 2023
6.93 M USD
Jan 1, 2024
-6.68 M USD
Jan 1, 2025
-14.94 M USD
The Curis Net Change in Cash history
YEARNet Change in CashYoY
-14.94 MUSD+123.46%
-6.68 MUSD-196.42%
6.93 MUSD-133.90%
-20.45 MUSD-77.20%
-89.69 MUSD-178.65%
114.03 MUSD-1,515.96%
-8.05 MUSD-45.04%
-14.65 MUSD-219.61%
12.25 MUSD-273.68%
-7.05 MUSD-127.83%
25.34 MUSD-1,474.33%
-1.84 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

Net Change in Cash of Curis is -14.94 M USD in 2025.

Net Change in Cash of Curis changed from -6.68 M USD to -14.94 M USD, representing a 123.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Curis since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Curis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curis

All Key Metrics — Curis